Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study
Neoadjuvante Camrelizumab plus Chemotherapie bei resektablem NSCLC Stadium IIIA–IIIB: integrierte multidimensionale Biomarkeranalyse aus einer Phase-II-Studie
Journal for ImmunoTherapy of Cancer · 2026-06 · 14 (6) · e015604
DOI: 10.1136/jitc-2026-015604 ↗Auf einen Blick
In einer einarmigen Phase-II-Studie bei resektablem NSCLC waren pCR, DFS und Sicherheit nach neoadjuvanter Camrelizumab-plus-Chemotherapie mit Biomarkerprofilen verknüpft.
Fragestellung
Welche Biomarker sind mit Therapieansprechen und Prognose bei resektablem NSCLC unter neoadjuvanter Camrelizumab-plus-Chemotherapie assoziiert?
Methode
Einarmige Phase-II-Studie mit drei Zyklen Camrelizumab plus Chemotherapie vor der Operation; Analyse von TME, peripherem Blut, Zytokinen, ctDNA und räumlichen Interaktionen.
Ergebnisse
30 Patient:innen eingeschlossen, 27 radikal reseziert. pCR 33,3 %, MPR 50,0 %, 2-Jahres-DFS 77,4 %; Grad≥3 UAW 13,3 %. pCR und DFS waren mit CD8+-, CCL3- und ctDNA-Markern assoziiert.
Schlussfolgerung der Autor:innen
Die Autoren schlussfolgern, dass CD8+ naïve-like T-Zellen, ihre räumliche Nähe zu Tumorzellen, CCL3 und ctDNA-Dynamiken potenzielle prognostische Biomarker sein könnten.
Kernaussagen
- pCR 33,3 % und MPR 50,0 % nach neoadjuvanter Therapie
- 2-Jahres-DFS 77,4 % bei medianem Follow-up von 27,2 Monaten
- ctDNA-Positivität nach Neoadjuvanz sagte kürzeres DFS voraus
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 19.06.2026. Verfasst von Guoxin Cai und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Shandong Province University "Youth Innovation Team Program”, Noncommunicable Chronic Diseases-National Science and Technology Major Project of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
This study evaluated biomarker profiles associated with therapeutic response and prognosis in resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant camrelizumab plus chemotherapy.
Methods
In this single-arm phase II trial, patients with resectable stage IIIA–IIIB NSCLC received three cycles of camrelizumab plus chemotherapy, followed by surgery. Primary endpoints were pathological complete response (pCR). Secondary endpoints included major pathological response (MPR), disease-free survival (DFS), and safety. Exploratory analyses assessed immune subsets in the tumor microenvironment (TME) and peripheral blood, cytokine profiles, circulating tumor DNA (ctDNA) dynamics, and spatial immune–tumor interactions.
Results
Thirty patients were enrolled (22 squamous, 8 adenocarcinoma); 27 underwent radical resection. The pCR and MPR rates were 33.3% and 50.0%, respectively. At a median follow-up of 27.2 months, the 2-year DFS rate was 77.4%. Grade≥3 treatment-related adverse events occurred in 13.3%. Achieving pCR was associated with higher baseline levels of CD8+ T cells and naïve-like T cells in both blood and TME. Elevated baseline CD8+ naïve-like T cells in both peripheral blood and tumor nests and their closer proximity to tumor cells correlated with improved DFS. Higher circulating baseline chemokine (C-C motif) ligand 3 (CCL3) levels were associated with both pCR and prolonged DFS. Postneoadjuvant treatment ctDNA positivity predicted shorter DFS, while longitudinal ctDNA monitoring identified relapse as early as 17.6 months before radiographic progression.
Conclusions
Baseline CD8+ naïve-like T-cell abundance and spatial proximity to tumor cells, circulating CCL3 levels, and ctDNA dynamics may serve as potential prognostic biomarkers in resectable NSCLC receiving neoadjuvant camrelizumab plus chemotherapy. Trial registration number NCT06241807 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- Department of Pneumosurgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- School of Clinical Medicine, Shandong Second Medical University, Weifang, China.
- Shandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
- Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of PET/CT Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Förderung
- National Natural Science Foundation of China
- Shandong Province University "Youth Innovation Team Program”
- Noncommunicable Chronic Diseases-National Science and Technology Major Project of China
- Shandong Provincial Medical Association
- Collaborative Academic Innovation Project of Shandong Cancer Hospital
- Jinan Clinical Medicine Science and Technology Innovation Program
- Natural Science Foundation of Shandong Province
Zitieren
APA
Cai, G., Song, P., Wang, Z., Zhao, J., Wang, K., Li, M., Wang, X., Zhu, J., Xu, J., Huang, B., Han, X., Zhou, H., Xie, C., Fu, S., Jia, H., Teng, F., Wang, S., Sun, H., Li, W., …, & Meng, X. (2026). Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study. Journal for ImmunoTherapy of Cancer, 14(6), e015604. https://doi.org/10.1136/jitc-2026-015604
Vancouver
Cai G, Song P, Wang Z, Zhao J, Wang K, Li M, et al. Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study. Journal for ImmunoTherapy of Cancer. 2026;14(6):e015604. doi:10.1136/jitc-2026-015604
BibTeX
@article{Cai2026,
author = {Cai, Guoxin and Song, Pingping and Wang, Zhendan and Zhao, Jiarui and Wang, Kaiyue and Li, Min and Wang, Xingpeng and Zhu, Jingyu and Xu, Jing and Huang, Baiyang and Han, Xiao and Zhou, Haiyan and Xie, Chao and Fu, Shuai and Jia, Hui and Teng, Feifei and Wang, Suzhen and Sun, Hongfu and Li, Wanhu and Yu, Jinming and Meng, Xue},
title = {Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {6},
pages = {e015604},
doi = {10.1136/jitc-2026-015604}
}
EUVIMED